AAD Updates Adult AD Guidelines: Here’s What To Know
Several new therapies have received a “strong” recommendation for the management of adult atopic dermatitis (AD) from the American Academy of Dermatology (AAD) in a focused guideline update. The list includes roflumilast cream 0.15% (Zoryve, Arcutis), tapinarof (Vtama, Organon), lebrikizumab (Ebglyss, Lilly), and nemolizumab (Nemluvio, Galderma). Specifically, tapinarof, lebrikizumab, and nemolizumab (with concomitant topical therapy) […]